Drug resistance of Streptococcus agalactiae isolated from female urogenital tract

doi:10.3969/j.issn.1673-8640.2017.011.012

Abstract

Abstract:

Objective To investigate the drug resistance of Streptococcus agalactiae isolated from female urogenital tract,and to provide a reference for clinical antibiotic usage. Methods Samples were collected from urogenital tract among females,and the drug resistance of Streptococcus agalactiae isolated from female urogenital tract was evaluated. Results A total of 77 isolates of Streptococcus agalactiae were collected,mainly from the secretions of female urogenital tract in Department of Gynaecology and Obstetrics. There were 94.8% females under 50 years old. The susceptibility test showed that tetracycline had the highest susceptibility rate（84.4%）,followed by erythromycin（63.6%） and clindamycin（29.9%）. Some isolates were resistant to levofloxacin（24.7%）,ciprofloxacin（24.7%） and nitrofurantoin（1.3%）,and some isolates had intermediate susceptibility to ciprofloxacin,nitrofurantoin and moxifloxacin. The isolates being resistant to tigecycline,quinupristin/dalfopristin,vancomycin,linezolid,ceftriaxone,ampicillin and penicillin were not found. The positive rate of D-inhibition zone trail was 75.0%,and 2 isolates of special resistant L-phenotype were determined. Conclusions Penicillin remains the first choice for the treatment of Streptococcus agalactiae infection. Inducible erythromycin-resistance and clindamycin-resistance exist. Hospitals should pay attention to special resistant phenotype and other bacterial drug resistance in order to prevent from multiple drug resistant isolates.

Key words: Streptococcus agalactiae, Female urogenital tract, Drug resistance

CLC Number:

R446.1

HUANG Yun, ZHANG Zhengyin, WANG Yating, JIN Ying, ZHENG Yijing, JIN Jun, XU Wenyi, YU Fengping. Drug resistance of Streptococcus agalactiae isolated from female urogenital tract[J]. Laboratory Medicine, 2017, 32(11): 994-998.

Figures/Tables 2

References 12

[1]	DONDERS G G,VEREECKEN A,BOSMANS E,et al.Definition of a type of abnormal vaginal flora that is distinct from bacterial vaginosis:aerobic vaginitis[J]. BJOG,2002,109(1):34-43.
[2]	Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing[S]. M100-S25,CLSI,2015.
[3]	高晶,刘晓艳. 女性泌尿生殖道无乳链球菌的耐药性分析[J]. 检验医学,2015,30(1):13-16.
[4]	林宇岚,陈守涛,荀振,等. 179株无乳链球菌的标本分布及耐药性分析[J]. 国际检验医学杂志,2015,37(10):1376-1378.
[5]	ELIKWU C,ODUYEBO O,ANORLU R,et al.Antibiotic susceptibility/resistant gene profiles of Group B streptococci isolates from pregnant women in a tertiary institution in Nigeria[J]. J Clin Sci,2016,13(3):132.
[6]	MINAMI M,NISHIYAMA H,IKEGAMI S,et al.Trend of invasive Streptococcus agalactiae at Tertiary Care Hospital in Japan[J]. J Biosci Med,2016,4(3):15-20.
[7]	SUNKARA B,BHEEMREDDY S,LORBER B,et al.Group B Streptococcus infections in non-pregnant adults: the role of immunosuppression[J]. Int J Infect Dis,2012,16(3):e182-e186.
[8]	郭素芳,张迎华,周敏,等. 泌尿生殖道分离无乳链球菌药物敏感性分析[J]. 检验医学,2008,23(6):612-614.
[9]	旷凌寒,母丽媛,苏敏,等. 孕晚期妇女产道定植性B群链球菌的耐药性及耐药机制研究[J]. 四川大学学报(医学版),2015,46(5):692-696.
[10]	EMANEINI M,JABALAMELI F,MIRSALEHIAN A,et al.Characterization of virulence factors,antimicrobial resistance pattern and clonal complexes of group B streptococci isolated from neonates[J]. Microb Pathog,2016,99:119-122.
[11]	王辉,宁永忠,陈宏斌,等. 常见细菌药物敏感性试验报告规范中国专家共识[J]. 中华检验医学杂志,2016,39(1):18-22.
[12]	赵丽琴. 育龄妇女分离无乳链球菌对氟喹诺酮类抗生素的耐药性及耐药机制研究[J]. 医学研究杂志,2015,44(8):149-151.

抗菌药物	耐药	中介	敏感
青霉素	0（0.0）	0（0.0）	77（100.0）
氨苄西林	0（0.0）	0（0.0）	77（100.0）
头孢曲松	0（0.0）	0（0.0）	77（100.0）
莫西沙星	0（0.0）	8（10.4）	69（89.6）
利奈唑胺	0（0.0）	0（0.0）	77（100.0）
万古霉素	0（0.0）	0（0.0）	77（100.0）
奎奴普丁/达福普汀	0（0.0）	0（0.0）	77（100.0）
替加环素	0（0.0）	0（0.0）	77（100.0）
呋喃妥因	1（1.3）	2（2.6）	74（96.1）
环丙沙星	19（24.7）	1（1.3）	57（74.0）
左氧氟沙星	19（24.7）	0（0.0）	58（75.3）
克林霉素	23（29.9）	0（0.0）	54（70.1）
红霉素	49（63.6）	0（0.0）	28（36.4）
四环素	65（84.4）	0（0.0）	12（15.6）

抗菌药物	耐药	中介	敏感
青霉素	0（0.0）	0（0.0）	77（100.0）
氨苄西林	0（0.0）	0（0.0）	77（100.0）
头孢曲松	0（0.0）	0（0.0）	77（100.0）
莫西沙星	0（0.0）	8（10.4）	69（89.6）
利奈唑胺	0（0.0）	0（0.0）	77（100.0）
万古霉素	0（0.0）	0（0.0）	77（100.0）
奎奴普丁/达福普汀	0（0.0）	0（0.0）	77（100.0）
替加环素	0（0.0）	0（0.0）	77（100.0）
呋喃妥因	1（1.3）	2（2.6）	74（96.1）
环丙沙星	19（24.7）	1（1.3）	57（74.0）
左氧氟沙星	19（24.7）	0（0.0）	58（75.3）
克林霉素	23（29.9）	0（0.0）	54（70.1）
红霉素	49（63.6）	0（0.0）	28（36.4）
四环素	65（84.4）	0（0.0）	12（15.6）

红霉素	克林霉素	株数	D试验阳性（株数）	备注
耐药	耐药	21	-
敏感	敏感	26	-
耐药	敏感	28	21	D试验阳性率75.0%
敏感	耐药	2	-	2株耐药性修改敏感→中介

红霉素	克林霉素	株数	D试验阳性（株数）	备注
耐药	耐药	21	-
敏感	敏感	26	-
耐药	敏感	28	21	D试验阳性率75.0%
敏感	耐药	2	-	2株耐药性修改敏感→中介

[1]	WANG Chao, ZHAO Yu. Research progress on formation mechanism and eradication strategy of bacterial persisters [J]. Laboratory Medicine, 2023, 38(8): 790-795.
[2]	ZHU Yurong, ZHANG Dan, HE Yaxing, LI Jingjing, HUANG Jing, LI Ting, LIU Peng, LIU Ronghua. Classification and epidemiology characteristics of Klebsiella pneumoniae isolated from clinic [J]. Laboratory Medicine, 2023, 38(5): 435-440.
[3]	FANG Yongmei, ZHANG Yan, XU Xueying, ZHONG Feng. Correlation of Staphylococcus aureus drug resistance with drug resistance genes and virulence genes [J]. Laboratory Medicine, 2023, 38(4): 357-361.
[4]	WANG Jiawei, ZHU Weinan, CHEN Yingying, JI Ping, WANG Ying. Clinical characteristics，molecular typing and drug resistance genes of carbapenem-resistant Klebsiella pneumoniae isolated from blood culturing [J]. Laboratory Medicine, 2023, 38(4): 362-367.
[5]	REN Yanfei, ZHANG Min, YANG Tao, LI Rongkai, LIANG Xin. Analysis of pathogenic epidemiology of patients with lower respiratory tract infection in respiratory intensive care unit [J]. Laboratory Medicine, 2023, 38(2): 157-162.
[6]	DENG Chen, DAI Jiaze, QIU Lihong, SHEN Weiting, CAI Mufa, LUO Wenying. Molecular epidemic characteristics of hypervirulent Klebsiella pneumoniae in Zhanjiang [J]. Laboratory Medicine, 2023, 38(11): 1026-1031.
[7]	RU Haohao, CHEN Lianyong, YANG Xing, CHEN Tao, YAN Shuangqun, XU Lin. Analysis of rifampicin resistance in Mycobacterium tuberculosis determined by Xpert MTB/RIF and phenotypic drug susceptibility test [J]. Laboratory Medicine, 2023, 38(11): 1032-1035.
[8]	WANG Su, DING Li, JIANG Wenrong, MIAO Yingxin, ZHANG Yanmei, ZHAO Hu. Research progress on drug resistance and treatment strategies of hypervirulent Klebsiella pneumoniae [J]. Laboratory Medicine, 2023, 38(1): 81-86.
[9]	HAO Jiahui, YANG Zehua. Research progress of bacterial integron determination methods [J]. Laboratory Medicine, 2022, 37(9): 887-891.
[10]	LIU Jingxian, CHEN Xingyue, ZHAO Jing, LIU Ying. Clinical characteristics and molecular epidemiology of Streptococcus agalactiae infection in non-pregnant adults [J]. Laboratory Medicine, 2022, 37(8): 793-797.
[11]	LI Hua, WANG Weiliang, XIE Bei, YANG Yu, MENG Fanrong, WANG Nan, LIU Zhihui, ZHANG Yanbin. Feasibility of the determination of heterogeneous drug resistance to rifampicin in Mycobacterium tuberculosis by flow cytometry [J]. Laboratory Medicine, 2022, 37(6): 577-582.
[12]	SUN Xiaodan, LIU Yiwen, HE Yiqing, DU Yan, ZHANG Guoliang, GAO Feng, YANG Cuixia. Research progress on the role of estrogen receptor in osteosarcoma [J]. Laboratory Medicine, 2022, 37(4): 313-318.
[13]	WANG Jianying, WANG Shanshan, ZHU Jun, HUANG Xiaochun, WAN Yuxiang, LIU Yun. Distribution and drug resistance of respiratory infection pathogens in patients with lung cancer after chemotherapy [J]. Laboratory Medicine, 2022, 37(4): 356-359.
[14]	SUN Ying, LI Yi, YAN Wenjuan, JING Nan, MA Bing. Analysis of drug resistance of rare CRE and clinical application of carbapenem screening test in Henan [J]. Laboratory Medicine, 2022, 37(2): 146-149.
[15]	WANG Lixin, SU Yunfu, WANG Yi. Research progress on the drug resistance mechanism of clinical pathogens to fosfomycin [J]. Laboratory Medicine, 2022, 37(10): 993-997.